City of Hope Launching Trial on Possible Cure for Type 1 Diabetes
City of Hope, a Healthcare Leadership Council member, is currently enrolling patients for a clinical trial involving an immunotherapy that could potentially cure Type 1 diabetes.
In Type 1 diabetes, the immune system attacks the pancreas and islets, which contain the cells that produce insulin. Inflammation from the attack destroys the beta cells, greatly reducing insulin production, causing blood sugar to rise. The trial treatment is designed to stop the autoimmune attack on the pancreatic islets and should be more effective for those recently diagnosed. If successful, progression of the disease will be halted, the remaining beta cells will produce insulin, and the course of the disease can be reversed.
Dr. Ping H. Wang, professor and chair of City of Hope's Department of Diabetes, Endocrinology and Metabolism said, "There are only a handful of clinical trials in the world right now aiming for a functional cure, and this is one of them. If you have recently been diagnosed, this is an opportunity to be involved in a trial that might eventually lead to a cure."
LabCorp Offers New Test to Detect Unintentional Gluten Consumption
The number of Americans with celiac disease, an autoimmune disease caused by a response to dietary items containing gluten, is rising. LabCorp, a Healthcare Leadership Council member, is now the first commercial laboratory in the United States to offer a test that can help individuals detect unintentional gluten consumption.
In one study of celiac patients on gluten-free diets, 67 percent of participants with persistent symptoms had detectable levels of gluten. This highlights the importance of testing, which can help individuals better understand the levels of gluten in their system and identify what food or consumable products may have caused their symptoms.
Dr. Marcia Eisenberg, LabCorp Diagnostics chief scientific officer, said, "For people with celiac disease and other gluten sensitivities, accidental gluten consumption can occur even when attempting strict adherence to a gluten-free diet--making testing an essential part of any attempt to remain symptom free. Labcorp's innovative, newly offered test option goes beyond a simple confirmation of recent gluten exposure by measuring the amount of gluten detected in a person's stool sample. This gives health care providers and their patients additional information to guide dietary decisions to help reduce gluten consumption, as well as the impact resulting symptoms have on patients' lives."